Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an <i>HLA-DRB1-MET</i> Gene Fusion

Abstract excerpt

Non–small-cell lung cancer (NSCLC) is a disease in which tumor growth is commonly driven by alterations along the receptor tyrosine kinase–RAS-RAF–mitogen-activated protein kinase pathway. Consequently, activated kinases along this axis represent attractive therapeutic targets. Activation of kinases can occur via multiple mechanisms at the genetic level, including mutation, amplification, and rearrangement/fusion...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytokine Signaling Pathways and Interactions
• Share to Lung Cancer Treatments and Mutations
• Share to PI3K/AKT/mTOR signaling in cancer